<DOC>
	<DOCNO>NCT00115986</DOCNO>
	<brief_summary>The purpose research study compare body reacts different strength new H5N1 flu vaccine . The study also look antibody make subject receives H5N1 flu vaccine . The vaccine give shot arm . Participants randomly assign receive 1 4 different dosage vaccine placebo ( dummy ) dose vaccine . Study procedure include physical exam , urine pregnancy test woman , blood sample . Participants ask complete diary record temperature , medication take , side effect vaccine . Volunteers involve study procedure approximately 7 month . The study enroll 450-470 healthy participant , age 18-64 .</brief_summary>
	<brief_title>A/H5N1in Adult - Aventis</brief_title>
	<detailed_description>Approximately 450 healthy adult , 18 64 year old , inclusive , enrolled multicenter , randomize , double-blinded , placebo-controlled , dose-ranging clinical trial . The study conduct 2 stage . During Stage I , 113 subject meet entry criterion study randomize receive saline placebo , 7.5 , 15 , 45 , 90 mcg influenza A/H5N1 vaccine intramuscular injection approximate 1:2:2:2:2 ratio ( N=25/vaccine dose group 13 placebo group ) . Subjects receive 2 dos separate approximately 28 day . Vaccine administration perform unblinded vaccine administrator , involved subsequent assessment . Subjects observe clinic 15 30 minute inoculation , subject maintain memory aid record oral temperature systemic local AEs 7 day immunization . Subjects contact telephone Day 2 immunization ass occurrence AEs , return Day 7 AE concomitant medication assessment , target physical examination ( indicate ) , review memory aid . Serum immunogenicity evaluation obtain prior first vaccination ( ie , screening Stage I Day 0 Stage II ) , prior second vaccination , Day 28 , Days 56 208 . All available 7-day safety data follow first dose vaccine 113 subject enrolled Stage I review Safety Monitoring Committee ( SMC ) prior enrollment remain subject ( Stage II ) , follow accord protocol . All available 7-day safety data follow second dose vaccine subject enrol Stage I also review SMC prior administer second dose vaccine subject Stage II . This study link DMID protocol 07-0022 , 05-0006 , 05-0090 08-0059 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion participate study : 1 . Male nonpregnant female ( indicated negative urine pregnancy test immediately prior vaccine administration ) age 18 64 year , inclusive . 2 . Women childbearing potential risk become pregnant must agree practice adequate contraception ( ie , barrier method , abstinence , license hormonal method ) entire study period . 3 . Is good health , determine vital sign ( heart rate , blood pressure , oral temperature ) , medical history target physical examination base medical history . 4 . In Stage I subject , normal laboratory value Hgb , WBC , Plt , ALT , creatinine prior first immunization . 5 . Able understand comply plan study procedure . 6 . Provides informed consent prior study procedure available study visit . Subjects meet follow exclusion criterion baseline exclude study participation : 1 . Has know allergy eggs component vaccine . 2 . Has positive urine pregnancy test prior vaccination ( female childbearing potential ) woman breastfeed . 3 . Is undergoing immunosuppression result underlie illness treatment . 4 . Has active neoplastic disease history hematologic malignancy . 5 . Is use oral parenteral steroid , highdose inhaled steroid ( &gt; 800 µg/day beclomethasone dipropionate equivalent ) immunosuppressive cytotoxic drug . 6 . Has history receive immunoglobulin blood product within 3 month prior enrollment study . 7 . Has receive license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrollment study . 8 . Has acute chronic medical condition , opinion investigator , would render vaccination unsafe would interfere evaluation response ( include , limited : know chronic liver disease , significant renal disease , unstable progressive neurological disorder , diabetes mellitus , transplant recipient ) . 9 . Has history severe reaction follow immunization contemporary influenza virus vaccine . 10 . Has acute illness , include oral temperature great 100.4ºF , within 1 week vaccination . 11 . Received experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 1 month prior enrollment study , expect receive experimental agent 7month study period . 12 . Has condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>A/H5N1 , Influenza , Vaccine , parent protocol</keyword>
</DOC>